IP Library › Patent Application 10608886
Patent Application
App. No. 10/608,886

Compositions and methods comprising protein activated receptor antagonists

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
10/608,886
Abstract

Compositions and methods comprising protein activated receptor antagonists are provided More particularly, the present invention relates to the use of proteins, peptides and biomolecules that bind to protein activated receptor 2, and inhibit the processes associated with the activation of that receptor. More specifically, the present invention provides novel compositions and methods for the treatment of disorders and diseases such as those associated with abnormal cellular proliferation, angiogenesis, inflammation and cancer.

Claims (21)

1 - 20 . (canceled)

21 . A composition for inhibiting protein activated receptor activity associated with skin disorders comprising a protein, peptide, biomolecule or active fragment thereof.

22 . The composition of claim 21 wherein the protein activated receptor comprises PAR-1, PAR-2, PAR-3 or PAR-4.

23 . The composition of claim 21 wherein the protein, peptide, or biomolecule comprises LIGK (SEQ ID NO:1), LIGKV (SEQ ID NO:2), KGIL (SEQ ID NO:3), KGI (SEQ ID NO:4), AGI (SEQ ID NO:5), IGA (SEQ ID NO:6), KGA (SEQ ID NO:7), KGA (SEQ ID NO:8), KAI (SEQ ID NO:9), IAK (SEQ ID NO:10), RGI (SEQ ID. NO:11), IGR (SEQ ID NO:12), Dab-GI (SEQ ID NO:13 ), Dap-GI (SEQ ID NO:14), IG-Dab (SEQ ID NO:15 ), IG-Dap (SEQ ID NO:16), LIG-Dab (SEQ ID NO:17), Dab-GIL (SEQ ID NO:18), LIG-Dap (SEQ ID NO:19), Dap-GIL (SEQ ID NO:20), LIG-Orn (SEQ ID NO:21), Orn-GIL (SEQ ID: 22), Orn-GI (SEQ ID NO:23), IG-Orn (SEQ ID NO:24), ENMD 545, ENMD 547 and active fragments thereof.

24 . The composition of claim 23 , wherein the protein activated receptor comprises PAR-2.

25 . The composition of claim 21 , wherein the protein activated receptor comprises PAR-2 and wherein the wherein the protein, peptide, or biomolecule comprises LIGK (SEQ ID NO:1).

26 . The composition of claim 21 , wherein the protein activated receptor comprises PAR-2 and wherein the wherein the protein, peptide, or biomolecule comprises ENMD 547.

27 . The composition of claim 21 , further comprising a pharmaceutically acceptable carrier.

28 . The composition of claim 21 , wherein the skin disorder comprises psoriasis, telangiectasia psoriasis, scleroderma, wound healing, delayed wound healing, hand foot and mouth disease, hair growth, rheumatoid arthritis, rosacea, skin warts, scars, Bechet's disease and inflammatory disease.

29 . The composition of claim 21 , wherein the skin disorder comprises eczema, dermatitis, seborrheic dermatitis, contact dermatitis, atopic dermatitis, nummular dermatitis, chronic dermatitis, Lichen Simplex Chronicus, stasis dermatitis, and generalized exfoliative dermatitis.

30 . The composition of claim 21 , wherein the skin disorder comprises psoriasis.

31 . A method for inhibiting protein activated receptor activity associated with skin disorders in a subject comprising administering to said subject protein, peptide, biomolecule or active fragment thereof.

32 . The method of claim 31 , wherein the protein activated receptor comprises PAR-1, PAR-2, PAR-3 or PAR-4.

33 . The method of claim 31 , wherein the protein, peptide, or biomolecule comprises LIGK (SEQ ID NO:1), LIGKV (SEQ ID NO:2), KGIL (SEQ ID NO:3), KGI (SEQ ID NO:4), AGI (SEQ ID NO:5), IGA (SEQ ID NO:6), KGA (SEQ ID NO:7), KGA (SEQ ID NO:8), KAI (SEQ ID NO:9), IAK (SEQ ID NO:10), RGI (SEQ ID. NO:11), IGR (SEQ ID NO:12), Dab-GI (SEQ ID NO:13 ), Dap-GI (SEQ ID NO:14), IG-Dab (SEQ ID NO:15 ), IG-Dap (SEQ ID NO:16), LIG-Dab (SEQ ID NO:17), Dab-GIL (SEQ ID NO:18), LIG-Dap (SEQ ID NO:19), Dap-GIL (SEQ ID NO:20), LIG-Orn (SEQ ID NO:21), Orn-GIL (SEQ ID: 22), Orn-GI (SEQ ID NO:23), IG-Orn (SEQ ID NO:24), ENMD 545, ENMD 547 and active fragments thereof.

34 . The method of claim 31 , wherein the protein activated receptor comprises PAR-2.

35 . The method of claim 31 , wherein the protein activated receptor comprises PAR-2 and wherein the wherein the protein, peptide, or biomolecule comprises LIGK (SEQ ID NO:1).

36 . The method of claim 31 , wherein the protein activated receptor comprises PAR-2 and wherein the wherein the protein, peptide, or biomolecule comprises ENMD 547.

37 . The method of claim 31 , further comprising a pharmaceutically acceptable carrier.

38 . The composition of claim 31 , wherein the skin disorder comprises psoriasis, telangiectasia psoriasis, scleroderma, wound healing, delayed wound healing, hand foot and mouth disease, hair growth, rheumatoid arthritis, rosacea, skin warts, scars, and inflammatory disease.

39 . The composition of claim 31 , wherein the skin disorder comprises eczema, dermatitis, seborrheic dermatitis, contact dermatitis, atopic dermatitis, nummular dermatitis, chronic dermatitis, Lichen Simplex Chronicus, stasis dermatitis, and generalized exfoliative dermatitis.

40 . The composition of claim 31 , wherein the skin disorder comprises psoriasis.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 24, 2003
From: HEMBROUGH, TODD; PRIBLUDA, VICTOR
To: ENTREMED, INC.
Reel/Frame 014745/0162 →